Active, not recruitingPhase 2NCT06519097

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Studying Intraductal papillary mucinous carcinoma of pancreas

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
Mokenge P Malafa, MD, FACS, MD
Moffitt Cancer Center
Intervention
Vitamin E Delta Tocotrienol(drug)
Enrollment
4 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (2)

Collaborators

American River Nutrition, LLC · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06519097 on ClinicalTrials.gov

Other trials for Intraductal papillary mucinous carcinoma of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Intraductal papillary mucinous carcinoma of pancreas

← Back to all trials